Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Sera Prognostics, Inc. (NASDAQ:SERA) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 844,400 shares, a drop of 19.6% from the December 31st total of 1,050,000 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average daily trading volume, of 102,700 shares, the short-interest ratio is currently 8.2 days.

Insider Buying and Selling at Sera Prognostics

In related news, insider Robert Gardner Harrison sold 14,209 shares of Sera Prognostics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the completion of the sale, the insider now owns 116,837 shares of the company’s stock, valued at approximately $863,425.43. The trade was a 10.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Zhenya Lindgardt sold 12,075 shares of Sera Prognostics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $88,389.00. Following the completion of the sale, the chief executive officer now directly owns 819,758 shares of the company’s stock, valued at approximately $6,000,628.56. The trade was a 1.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,215 shares of company stock valued at $666,835 in the last quarter. Company insiders own 15.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC increased its holdings in shares of Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Sera Prognostics in the second quarter valued at about $68,000. SG Americas Securities LLC bought a new stake in Sera Prognostics in the third quarter valued at about $78,000. Prime Capital Investment Advisors LLC bought a new stake in Sera Prognostics in the third quarter valued at about $104,000. Finally, Jane Street Group LLC increased its stake in Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after acquiring an additional 2,826 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Trading Down 2.7 %

Sera Prognostics stock traded down $0.18 on Friday, reaching $6.47. 112,445 shares of the stock were exchanged, compared to its average volume of 92,625. The stock has a market cap of $218.49 million, a PE ratio of -6.54 and a beta of 0.86. Sera Prognostics has a twelve month low of $4.98 and a twelve month high of $12.35. The firm has a fifty day moving average price of $7.36 and a two-hundred day moving average price of $7.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter last year, the firm posted ($0.23) EPS. Equities analysts anticipate that Sera Prognostics will post -0.96 EPS for the current fiscal year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.